Literature DB >> 11807690

The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions.

Julie M Villanueva1, Tedd V Ellerbrock, Jeffrey L Lennox, Timothy J Bush, Thomas C Wright, Melody Pratt-Palmore, Tammy Evans-Strickfaden, Lois J Conley, Cathy Schnell, Clyde E Hart.   

Abstract

To determine whether the menstrual cycle affects human immunodeficiency virus (HIV) type 1 levels in vaginal secretions, vaginal lavage samples were collected at 7, 14, and 21 days after initiation of menses, to compare virus levels during the follicular, ovulatory, and luteal phases. During 33 menstrual cycles in 25 women, HIV-1 RNA levels in vaginal secretions ranged from <1000 to 5.3x10(7) copies per lavage, and weekly changes ranged from <0.5 to 2.5 log(10) copies per lavage. HIV-1 RNA levels in vaginal lavage samples from days 7, 14, and 21 were not significantly different. No discernible pattern was found in changes of vaginal virus loads (VVLs) during the menstrual cycle. VVLs were not correlated with plasma estradiol or progesterone levels (P>.05). These results suggest that hormonal changes during the menstrual cycle do not have a significant effect on HIV-1 RNA levels in vaginal secretions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807690     DOI: 10.1086/338447

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Increased levels of HIV-1-infected cells in endocervical secretions after the luteinizing hormone surge.

Authors:  Sarah Benki; Sara B Mostad; Barbra A Richardson; Kishorchandra Mandaliya; Joan K Kreiss; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

2.  17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription.

Authors:  Erika L Szotek; Srinivas D Narasipura; Lena Al-Harthi
Journal:  Virology       Date:  2013-06-12       Impact factor: 3.616

Review 3.  Clinical parameters essential to methodology and interpretation of mucosal responses.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

4.  Characterization of the Genital Microenvironment of Female Rhesus Macaques Prior to and After SIV Infection.

Authors:  Whitney A Nichols; Leslie Birke; Jason Dufour; Nisha Loganantharaj; Gregory J Bagby; Steve Nelson; Patricia E Molina; Angela M Amedee
Journal:  Am J Reprod Immunol       Date:  2015-08-20       Impact factor: 3.886

5.  Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding.

Authors:  James Homans; Shawna Christensen; Tracey Stiller; Chia-Hao Wang; Wendy Mack; Kathryn Anastos; Howard Minkoff; Mary Young; Ruth Greenblatt; Mardge Cohen; Howard Strickler; Roksana Karim; Lashonda Yvette Spencer; Eva Operskalski; Toinette Frederick; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

Review 6.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

7.  Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies.

Authors:  Mimi Ghosh; John V Fahey; Zheng Shen; Timothy Lahey; Susan Cu-Uvin; Zhijin Wu; Kenneth Mayer; Peter F Wright; John C Kappes; Christina Ochsenbauer; Charles R Wira
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

8.  Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer.

Authors:  Jeny Ghartey; Andrea Kovacs; Robert D Burk; L Stewart Massad; Howard Minkoff; Xianhong Xie; Gypsyamber Dʼsouza; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Mark H Einstein; Christine Colie; Kathryn Anastos; Isam-Eldin Eltoum; Betsy C Herold; Joel M Palefsky; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

9.  HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.

Authors:  Anandi N Sheth; Tammy Evans-Strickfaden; Richard Haaland; Amy Martin; Chelsea Gatcliffe; Adebola Adesoye; Michael W Omondi; L Davis Lupo; Damien Danavall; Kirk Easley; Cheng-Yen Chen; Chou-Pong Pau; Clyde Hart; Igho Ofotokun
Journal:  J Infect Dis       Date:  2014-03-18       Impact factor: 5.226

10.  Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.

Authors:  Stephen E Hawes; Papa Salif Sow; Joshua E Stern; Cathy W Critchlow; Geoffrey S Gottlieb; Nancy B Kiviat
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.